Deprenyl
Template:Short description Template:Drugbox
Deprenyl, also known by its developmental code name E-250 and as N-propargylmethamphetamine, is the racemic mixture of D-deprenyl and L-deprenyl (selegiline).<ref name="Parnham1993">Template:Cite book</ref><ref name="HeinonenLammintausta1991">Template:Cite journal</ref><ref name="Miklya2016">Template:Cite journal</ref> It was discovered in 1961 in Hungary at Chinoin Pharmaceutical Company by Zoltan Ecseri and József Knoll, was patented in 1962, and was first described in the literature in 1964 or 1965.<ref name="Parnham1993" /><ref name="HeinonenLammintausta1991" /><ref name="Miklya2016" />
The drug is a monoamine oxidase inhibitor and norepinephrine–dopamine releasing agent.<ref name="HeinonenLammintausta1991" /> It is a prodrug of methamphetamine and amphetamine, which mediates the latter action.<ref name="Tipton2018">Template:Cite journal</ref> Deprenyl was studied clinically at high doses of 50 to 100Template:Nbspmg/day and was described as a psychostimulant and antidepressant.<ref name="HeinonenLammintausta1991" /><ref name="Parnham1993" /><ref name="Miklya2016" /> At lower doses, selective MAO-B inhibition would be expected, but at these higher doses, dual inhibition of MAO-A and MAO-B would occur, on the basis of L-deprenyl.<ref name="Mahmood1997">Template:Cite journal</ref>
Subsequent to its synthesis, the stereoisomers of deprenyl were separated.<ref name="Parnham1993" /> The dextrorotatory isomer, D-deprenyl, was found to be more toxic, producing effects like hyperthermia and more potent psychostimulation in rodents.<ref name="Parnham1993" /><ref name="HeinonenLammintausta1991" /> The levorotatory isomer, selegiline, was much more potent as an MAO-B inhibitor, and was subsequently developed for the treatment of Parkinson's disease and depression.<ref name="HeinonenLammintausta1991" /><ref name="Miklya2016" />
Deprenyl is reported to result in side effects including agitation, anxiety, and sleep disturbances more often than selegiline.<ref name="Knoll1983">Template:Cite journal</ref>
Similarly to selegiline, deprenyl is a catecholaminergic activity enhancer (CAE).<ref name="KnollMiklya1994">Template:Cite journal</ref> Both enantiomers of deprenyl, D-deprenyl and selegiline, are active in this respect, but selegiline is slightly more potent than D-deprenyl.<ref name="KnollMiklya1994" />
See also
References
Template:Monoamine metabolism modulators Template:Monoaminergic activity enhancers Template:Monoamine releasing agents Template:Sigma receptor modulators {{#invoke:Navbox|navbox}}